Compugen reported $94.55M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
Arca Biopharma USD 50.17M 1.45M Mar/2026
aTyr Pharma USD 62.99M 46.35M Mar/2026
Bio Path USD 9.34M 100K Mar/2026
Brainstorm Cell Therapeutics USD 11.04M 0 Mar/2026
Cara Therapeutics USD 9.38M 2.01K Mar/2026
Clal Biotechnology ILS 1.61M 0 Dec/2022
Compugen USD 94.55M 1000 Mar/2026
Immunic USD 120.38M 21.73M Dec/2025
Minerva Neurosciences USD 1000 0 Sep/2024
RedHill Biopharma USD 50.92B 17.62B Dec/2025
TherapeuticsMD USD 11K 0 Sep/2023